News

Filter

Current filters:

Biocon

1 to 9 of 18 results

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

05-06-2014

US pharma major Bristol-Myers Squibb and Syngene International, India’s largest contract research organization,…

BioconBiotechnologyBristol-Myers SquibbIndiaResearchSyngene

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

India loses its attraction for pharma clinical trials, as domestic regulations tighten

India loses its attraction for pharma clinical trials, as domestic regulations tighten

27-01-2014

Considered a global clinical trial hub three years ago, India has suffered a series of setbacks, with…

Asia-PacificBioconIndiaPharmaceuticalPiramal HealthcareRegulationResearch

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Biocon introduces biosimilar trastuzumab for breast cancer in India

20-01-2014

India-based biotech firm Biocon (BSE: 532523) has introduced Canmab, a biosimilar trastuzumab, for the…

BioconBiosimilarsIndiaMarkets & MarketingOncologytrastuzumab

Biocon and Quark Pharma collaborate on novel siRNA based therapeutics

18-12-2013

India-based biotech firm Biocon and the USA’s Quark Pharmaceuticals have entered into a licensing and…

BioconBiotechnologyLicensingOphthalmicsQuark PharmaceuticalsResearch

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top